ABBOTT PARK, Ill., Sept. 18, 2017
/PRNewswire/ -- Abbott (NYSE: ABT) announced today that
it is extending its previously announced tender offer to purchase
for cash all outstanding shares of Series B Convertible Perpetual
Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at
a price of $402.00 per share of
Preferred Stock, plus accrued but unpaid dividends to, but not
including, the settlement date of the tender offer, net to the
seller thereof in cash, without interest thereon and subject to any
withholding of taxes required by applicable law (the "Offer"). The
Offer is being made pursuant to an Offer to Purchase, dated
July 17, 2017 (the "Offer to
Purchase"), and in connection with Abbott's previously announced
agreement to acquire Alere (the "Merger"). The Merger is not
conditioned upon, or otherwise subject to, the completion of the
Offer.
The Offer is being extended to allow additional time for the
consummation of the Merger, which is a condition to the completion
of the Offer. The Offer was previously scheduled to expire at
11:59 p.m., New York City time, on Friday, Sept. 15, 2017 and will now expire at
11:59 p.m., New York City time, on Friday, Sept. 29, 2017 (such date and time, as it
may be extended or earlier terminated, the "Expiration Date"). If,
at the Expiration Date, any of the conditions to the Offer have not
been satisfied or waived, Abbott may elect to further extend the
Offer for any length of time and in its sole discretion, but is
under no obligation to do so.
American Stock Transfer & Trust Company, LLC, the depositary
for the Offer, has advised Abbott that, as of 11:59 p.m., New York
City time, on Friday, Sept. 15,
2017, greater than 90% of the issued and outstanding shares
of Preferred Stock had been tendered in the Offer. Holders of
Preferred Stock who have already tendered their shares do not have
to re-tender their shares or take any other action as a result of
the extension of the expiration of the Offer.
For more information, contact Barclays Capital Inc., the
Dealer-Manager for the Offer, or D.F.
King & Co., Inc., the Information Agent for the
Offer.
D.F. King &
Co., Inc.
|
Barclays
|
48 Wall Street – 22nd
Floor
|
745 Seventh Avenue,
5th Floor
|
New York, New York
10005
|
New York, New York
10019
|
|
Attn: Liability
Management Group
|
Banks and Brokers
Call: (212) 269-5550
|
|
All others call
Toll-Free: (877) 283-0316
|
Banks and Brokers
Call: (212) 528-7581
|
Email:
alr@dfking.com
|
All others call
Toll-Free: (800) 438-3242
|
Additional Information and Where to Find It
This
announcement is neither an offer to purchase nor a solicitation of
an offer to sell securities. The Offer for the outstanding shares
of Alere's Preferred Stock described in this news release is being
made pursuant to an Offer to Purchase and related materials that
Abbott has filed with the Securities and Exchange Commission (the
"SEC") pursuant to a Schedule TO. The Schedule TO, Offer to
Purchase, a related letter of transmittal and other Offer documents
contain important information that should be read carefully before
any decision is made with respect to the Offer. These materials
(and all other documents Abbott has filed with the SEC) will be
available at no charge on the SEC's website at www.sec.gov.
About Abbott
Abbott is a global healthcare company
devoted to improving life through the development of products and
technologies that span the breadth of healthcare. With a portfolio
of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott
serves people in more than 150 countries and employs approximately
94,000 people.
Visit Abbott at www.abbott.com and connect with us on
Twitter at @AbbottNews.
A Caution Concerning Forward-Looking Statements
Some
statements in this news release may be forward-looking statements.
Abbott cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Item
1A, "Risk Factors," in Abbott's Annual Report on Form 10-K for the
year ended Dec. 31, 2016, and are
incorporated by reference. Abbott undertakes no obligation to
release publicly any revisions to forward-looking statements as a
result of subsequent events or developments, except as required by
law.
View original content with
multimedia:http://www.prnewswire.com/news-releases/abbott-announces-extension-of-cash-tender-offer-for-all-outstanding-shares-of-series-b-convertible-perpetual-preferred-stock-of-alere-inc-300520703.html
SOURCE Abbott